CA2547757A1 - Monoparamunity inducers based on attenuated rabbit myxoma viruses - Google Patents

Monoparamunity inducers based on attenuated rabbit myxoma viruses Download PDF

Info

Publication number
CA2547757A1
CA2547757A1 CA002547757A CA2547757A CA2547757A1 CA 2547757 A1 CA2547757 A1 CA 2547757A1 CA 002547757 A CA002547757 A CA 002547757A CA 2547757 A CA2547757 A CA 2547757A CA 2547757 A1 CA2547757 A1 CA 2547757A1
Authority
CA
Canada
Prior art keywords
myxomavirus
passages
attenuated
myxomaviruses
monoparamunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002547757A
Other languages
English (en)
French (fr)
Inventor
Anton Mayr
Barbara Mayr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2547757A1 publication Critical patent/CA2547757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
CA002547757A 2004-01-23 2005-01-21 Monoparamunity inducers based on attenuated rabbit myxoma viruses Abandoned CA2547757A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004003572A DE102004003572A1 (de) 2004-01-23 2004-01-23 Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102004003572.5 2004-01-23
PCT/EP2005/000582 WO2005070453A1 (de) 2004-01-23 2005-01-21 Monoparamunitätsinducer basierend auf attenuierten myxomaviren des kaninchens

Publications (1)

Publication Number Publication Date
CA2547757A1 true CA2547757A1 (en) 2005-08-04

Family

ID=34800965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002547757A Abandoned CA2547757A1 (en) 2004-01-23 2005-01-21 Monoparamunity inducers based on attenuated rabbit myxoma viruses

Country Status (15)

Country Link
US (9) US7494799B2 (cg-RX-API-DMAC7.html)
EP (2) EP2327420A3 (cg-RX-API-DMAC7.html)
JP (1) JP4846598B2 (cg-RX-API-DMAC7.html)
KR (2) KR101209141B1 (cg-RX-API-DMAC7.html)
CN (1) CN1909923B (cg-RX-API-DMAC7.html)
AU (1) AU2005205912B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0506489A (cg-RX-API-DMAC7.html)
CA (1) CA2547757A1 (cg-RX-API-DMAC7.html)
DE (1) DE102004003572A1 (cg-RX-API-DMAC7.html)
EA (1) EA009937B1 (cg-RX-API-DMAC7.html)
IL (1) IL176634A (cg-RX-API-DMAC7.html)
NO (1) NO20063605L (cg-RX-API-DMAC7.html)
NZ (1) NZ548189A (cg-RX-API-DMAC7.html)
UA (1) UA91501C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005070453A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102005027956B4 (de) * 2005-06-16 2009-10-22 Mayr, Anton, Prof. Dr. Dr. h.c. mult. Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen
CN102230035B (zh) * 2011-07-06 2013-02-13 中华人民共和国江苏出入境检验检疫局 兔粘液瘤病毒pcr检测试剂盒及其应用
JP6370082B2 (ja) * 2014-04-07 2018-08-08 キヤノン株式会社 情報処理装置、情報処理方法、及びプログラム
JP2017083973A (ja) * 2015-10-23 2017-05-18 富士通株式会社 表示端末装置、表示制御方法および表示制御プログラム

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
DE4405841C1 (de) 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
KR100880765B1 (ko) * 2000-03-14 2009-02-02 버베리안 노딕 에이/에스 변형된 백시니아 바이러스 안카라(mva)의 변형 균주
AU4930001A (en) * 2000-04-03 2001-10-15 Univ Pittsburgh Cold-adapted equine influenza viruses
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
US8663622B2 (en) * 2002-12-16 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant vaccine viruses expressing IL-15 and methods using the same
US6960345B2 (en) * 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
WO2004078206A1 (en) * 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
DE102005027956B4 (de) * 2005-06-16 2009-10-22 Mayr, Anton, Prof. Dr. Dr. h.c. mult. Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen

Also Published As

Publication number Publication date
US20110014234A1 (en) 2011-01-20
US20100316671A1 (en) 2010-12-16
EA009937B1 (ru) 2008-04-28
JP2007534664A (ja) 2007-11-29
US7494799B2 (en) 2009-02-24
BRPI0506489A (pt) 2007-02-13
HK1095746A1 (en) 2007-05-18
US8039004B2 (en) 2011-10-18
EP1711204A1 (de) 2006-10-18
DE102004003572A1 (de) 2005-08-18
EP2327420A3 (de) 2011-07-06
US20120070464A1 (en) 2012-03-22
KR20120076396A (ko) 2012-07-09
WO2005070453A8 (de) 2006-08-03
JP4846598B2 (ja) 2011-12-28
US8034356B2 (en) 2011-10-11
EP2327420A2 (de) 2011-06-01
AU2005205912B2 (en) 2010-07-29
KR101209141B1 (ko) 2012-12-06
NO20063605L (no) 2006-08-09
EA200601361A1 (ru) 2006-12-29
US20120009217A1 (en) 2012-01-12
US20080267920A1 (en) 2008-10-30
US7691391B2 (en) 2010-04-06
CN1909923B (zh) 2012-10-03
NZ548189A (en) 2009-02-28
KR20060129221A (ko) 2006-12-15
US20070154455A1 (en) 2007-07-05
US20080213307A1 (en) 2008-09-04
US8142796B2 (en) 2012-03-27
IL176634A0 (en) 2006-10-31
CN1909923A (zh) 2007-02-07
WO2005070453A1 (de) 2005-08-04
US20120009654A1 (en) 2012-01-12
AU2005205912A1 (en) 2005-08-04
US20110020908A1 (en) 2011-01-27
US7939085B2 (en) 2011-05-10
IL176634A (en) 2011-03-31
UA91501C2 (ru) 2010-08-10

Similar Documents

Publication Publication Date Title
CN100540051C (zh) 用于接种新生儿的改良的安卡拉痘苗病毒
US8034356B2 (en) Monoparamunity inducers based on attenuated rabbit myxoma viruses
JP2007534664A5 (cg-RX-API-DMAC7.html)
MXPA06008005A (en) Monoparaimmunity inducers based on attenuated rabbit myxoma viruses
US20080305129A1 (en) Highly Attenuated Pox Virus Strains, Method for the Production Thereof and the Use Thereof as Paramunity Inducers or For Producing Vector Vaccines
HK1095746B (en) Monoparamunity inducers based on attenuated rabbit myxoma viruses
HK1078777B (en) Modified vaccinia virus ankara for the vaccination of neonates

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140716